Clinical trials are essential in developing new, improved, and more effective treatments and interventions. Without trials, researchers and professionals in the field cannot properly determine whether these new treatments and interventions are safe and effective.
Furthermore, when larger group testing occurs, this allows researchers to identify and ensure that any improvements resulting from the intervention occurs for as many people as possible and are not just occurring in one individual.
Ahead of the J.P. Morgan Health Conference in San Francisco in January 2023, Australian Health Journal met with Clinials CEO & Founder Maree Beare about developing the next generation recruitment platform and digital marketing service for clinical research. Maree talks about the reasons why clinical trials can fail and the importance of bringing participants much more closer to researchers.
With this need, the Clinials platform is geared towards patient centric trials and reducing site burden. The aim is to accelerate lifesaving medicines coming to market by connecting participants and researchers. The platform allows participants to come to researchers with their eligibility in hand among other capabilities.
Supporting CRO’s, sites and sponsors, the Clinials platform uses AI to convert complex trial protocol into plain language and pre-screening questions. This gives researchers the tools to communicate with their participants meaningfully. The plain language text can be used in a variety of situations like researcher led advertising, landing pages and plain language summaries.
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Surgeon receives global award for kidney transplant science
Commencing a new series called Pioneers in Health Care, is an interview with Professor Jeremy Chapman AC who for over 40 years, has been involved in nephrectomy, or kidney transplantation.
Honoured “for eminent service to medicine, particularly in the areas of clinical and biomedical research, to the development of ethical policy and practices for organ donation, acquisition and transplantation, and to renal medicine organisations and publications, Jeremy Chapman AC has played significant roles in development of kidney, pancreas and unrelated Bone Marrow Transplantation in Australia.
